The clinical, haematological and cytogenetic data for 20 patients with an acquired abnormality of 11q23 and 10p have been reviewed at this workshop. Patients predominantly presented with de novo AML M5a and the most common cytogenetic finding was an inversion of part of the long arm of chromosome 11 followed by a translocation between 11q and 10p. Band p12 represented the most common breakpoint on chromosome 10. The t(10;11) subgroup defined a subset of younger 11q23 patients, the majority of whom achieve a first complete remission despite the differing treatment regimens.
Introduction
Abnormalities affecting chromosome 11 band q23 occur in approximately 5% of acute leukaemias, predominantly in infant leukaemia, AML M4 and M5, ALL with biphenotypic features and secondary leukaemia following cytotoxic therapy with epipodophyllotoxins. 1, 2 At least 25 different partner loci have been found to rearrange with 11q23. The MLL gene [3] [4] [5] [6] has been shown to be disrupted as a result of rearrangement and in frame fusion with different partner genes. The t(10;11)(p11-13;q23) translocation represents one of the recurrent rearrangements which affects the 11q23 region. The partner gene, AF10, located in the region 10p11-13 was cloned from a patient with AML M5 7 and was shown to fuse to MLL in such a way that its leucine zipper domain was consistently juxtaposed to the N terminal region of MLL. 8 In contrast to the other rearrangements affecting 11q23, the AF10 partner gene is orientated in the opposite transcriptional direction and it is therefore not possible to generate the 5′ MLL-3′ AF10 fusion by invoking a simple reciprocal translocation event. 9 An inframe fusion therefore necessitates a more complex mechanism of rearrangement and it has been shown that some cases may display a more centromeric breakpoint on chromosome 11 (11q12-11q14) but still involve the MLL gene at 11q23. Molecular investigations using fluorescence in situ hybridization (FISH), RT-PCR and Southern blotting have demonstrated that these cases involve a three break rearrangement with inversion of (11)(q12-14q23) and translocation of the inverted 11q to 10p11-13. This results in the juxtaposition of 5′ MLL to 3′ AF10 which are then fused in the same orientation.
This rearrangement may be difficult to identify by Gbanding alone and has almost certainly been under recognized. The demonstration that an apparently reciprocal t(10;11)(p12;q23) may have 5′ MLL-3′ AF10 fusion indicates that these cases may contain a submicroscopic inversion of either 5′ MLL or 3′ AF10. The complexity of the t(10;11) rearrangement also accounts for the lack of expression of a reciprocal 5′ AF10-3′ MLL fusion in those patients investigated. 9 The criteria for the entry of patients to the Workshop included the recognition of an 11q23 breakpoint by cytogenetic analysis. A total of 20 patients with a 10p and 11q23 breakpoint were accepted to the study and this represented approximately 4% of all patients entered to the 11q23 Workshop. Cytogenetic, clinical and follow-up features of these patients are presented.
Materials and methods
The 20 patients had been collected through the EU Concerted Action Workshop on 11q23 initiative as described by SeckerWalker. 10 Karyotypes for the following two patients have been published previously: 91, 9 558.
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Patient data at diagnosis
The patient data and karyotype profiles of the 20 patients with t(10;11)(p11ෂ3;q23) are shown in Table 1 . The age distribution of patients was as follows: adults (Ͼ14 years) n = 3 (median age, 27 years), children (1-14 years) n = 11 (median age, 3 years), infants (Ͻ1 year) n = 6 (median age, 0.17 years). There were no differences in the male to female sex ratio of the children but all three adults were male and 5/6 infants were female. Fifteen patients had acute myeloid leukaemia (AML) predominantly of M5a FAB type, four patients had acute lymphoblastic leukaemia (ALL) and one had biphenotypic leukaemia (BIP). Central nervous system involvement in this group of 11q23 patients was rare (n = 2/18). The median white blood cell count (WBC) (×10 9 /l) and percentage of blasts in the bone marrow were 58.1 and 50, respectively, for the infants, 44.3 and 90, respectively, for the children and 32 and 95, respectively, for the adults. One patient had a secondary, therapy-related AML, an adult who had received lumbar irradiation, 12 the remainder of patients presented with de novo disease.
Immunophenotype of eight AML cases
Blast cell immunophenotype had been investigated in eight patients with AML. At least one pan-myeloid marker (CD13, CD33) was expressed in 7/8 cases. Markers of monocyte differentiation (CD14,CD11) were positive in 5/6 cases. TdT expression was absent and CD7 was rarely expressed. The stem cell marker CD34 was positive in 4/7 cases. Patient No. 477 (infant, 0.25 years) showed both CD10 and CD19 expression but of the other five cases tested for at least one Cytogenetic characteristics Table 1 shows karyotypes of the patients. In each case 10p11-13 was juxtaposed to 11q23 in one of four ways. Seven of the 20 patients showed an apparently simple reciprocal (two break) translocation t(10;11)(p11-13;q23). Twelve patients had an inversion of 11q13-11q23 combined with either a translocation of the inverted 11q to 10p11-13 (eight cases) or with insertion of inv(11)(q) to 10p (four cases). One patient had an inversion of 10p12-15 which was inserted into 11q23. Two of the 12 cases had a complex translocation with a third chromosome involved with 10p and 11q. Eleven cases had abnormalities additional to those detailed above.
Molecular cytogenetic or molecular studies
The cytogenetic abnormalities were confirmed by molecular studies in five cases, by FISH analysis in four patients, three of whom were also shown to have an MLL rearrangement or MLL-AF10 fusion by Southern blotting or RT-PCR. One additional patient was shown to be positive for a MLL rearrangement by Southern blotting. One patient (case 497) showed no evidence of a split MLL signal in the nuclei examined. MLL FISH probes will detect only 80% of MLL rearrangements therefore without further molecular analysis the presence of an MLL rearrangement in case 497 cannot be excluded.
Treatment and outcome
The median overall survival (OS) for 13 AML patients was 17.8 months and the median event-free survival (EFS) was 12.2 months. Patients were treated according to the treatment regimens of their referring centres. Five patients underwent a bone marrow transplant (BMT) (patients 124, 255, 611, 558 and 91), three patients received an autologous BMT whilst two had an allogeneic BMT. Despite such aggressive therapy one child and one adult died as a result of their leukaemia (patients 558 and 91). One child and two infants were still alive following BMT at 18.9, 60.6 and 74.7 months from diagnosis.
The remainder of patients were treated at nine different centres with combination chemotherapy. One of the seven children had relapsed 8.6 months from diagnosis and died, but the remaining six children were still in first remission with a median follow-up of 7.4 months (range 2.4 to 46.8 months). In contrast, none of the four infants treated by chemotherapy alone survived. One adult (patient 295) was still in first remission 5 months after diagnosis, but the other two adults died of leukaemia, 3.0 and 12.4 months from diagnosis. The infant with BIP never achieved remission and died 3 months from presentation of resistant CNS disease. There was no difference between those patients who had or did not have a BMT either for OS or EFS but the number of cases available for analysis was extremely small.
Discussion
Approximately 42 patients with t(10;11) have been reported to date, 13 two of whom are included in this Workshop (cases 558 and 91). The majority of cases previously reported had been diagnosed with AML predominantly M5 (50% of all cases) which is consistent with the findings of this Workshop. Only one case of AML, M4 and t(10;11) was submitted to the Workshop although previous reports suggest 25% of t(10;11) cases are seen in this FAB type. Approximately 15% of all patients with leukaemic blasts containing abnormalities of 11q23 and 10p and reported in the literature have had ALL, an incidence which is similar to that reported from this Workshop.
In the literature there are approximately equal numbers of patients with apparently reciprocal (two-breakpoint) translocations and with more complex rearrangement events involving at least three breakpoints. 13 The higher incidence of t(10;11) cases with three-breakpoint rearrangements in this Workshop (65% of cases) may reflect more recent awareness of these abnormalities, coupled with the use of FISH, RT-PCR and Southern blotting to confirm the abnormalities and the knowledge that AF10 and MLL are oppositely orientated and therefore cannot generate a fusion by a simple reciprocal translocation. The generation of a 5′ MLL-3′ AF10 fusion has been shown to be brought about by inversion of part of the long arm of chromosome 11 followed by a translocation to the short arm of chromosome 10, or an inverted insertion of part 11q into 10p. 9 Twelve patients in our study showed rearrangements of these kinds. One patient in the Workshop displayed a novel insertion of part of the short arm of 10p into 11q23 which has not previously been reported. Seven patients in the Workshop had a two-break, reciprocal translocation. Three of these seven patients were shown to involve a rearrangement of MLL and two showed MLL-AF10 fusion by RT-PCR. The mechanism by which cases generate the MLL-AF10 has yet to be elucidated but this may involve a submicroscopic inversion of either the MLL or the AF10 gene.
The most common breakpoint seen on chromosome 10 was band p12 (13/20 cases) which is consistent with findings from the literature. 13 Further molecular investigation would be required to establish whether the discrepancy in the breakpoint positions in the remainder of cases is an artefact of the banding method used (reverse (R) vs Giemsa (G) banding) and quality of the chromosomes. Band 11q13 is the loci most frequently involved with 11q23 in the inversion/insertion mechanism (7/12) although band 11q14 and the more telomeric 11q25 have also been implicated. The presence of additional chromosome abnormalities did not appear to be significant in terms of prognosis in the small group of patients entered to this Workshop. No recurrent additional changes were noted.
Although the numbers of cases are still relatively small, the t(10;11) translocation appears to define a subset of younger 11q23 patients. There were only three adults in this series, (median age 27 years, range 17-33 years), the median ages of children and infants was 3 years and 0.17 years, respectively. The three adults in our series were male. Beverloo et al 9 also remarked on the male predominance of this subgroup. In contrast, in this study, among six infants only one was male.
Patients with t(10;11) in our series appear to have longer survivals than the other 11q23 groups within the Workshop. Only one of the seven children had relapsed and died. One child had an event-free survival of nearly 4 years having been treated with chemotherapy alone, suggesting that it may be possible to cure a subset of children with t(10;11) using conventional chemotherapy. In the infant group, however, the only two patients surviving long-term had had a BMT. Hence BMT may represent the only possible means of achieving a cure for these infants.
Establishing the full nature of these events will require further molecular investigation. It has already been demonstrated that, in one example of the insertion and inversion of chromosome 11 material into the short arm of chromosome 10, the AF10 gene is split.
14 At one end a 5′ MLL/3′AF10 inframe fusion was found while at the other end of the insertion 5′ AF10 was fused out of frame to a novel gene, HEAB, which encodes a human homolog to a putative Caenorhabditis elegans ATP/GTP-binding protein. It is also of note that AF10 is one of the few partner genes for MLL which has been found rearranged with another gene. The cell line U937 has been shown to contain a translocation t(10;11)(p13;q14) which results in a fusion between AF10 and a novel gene, CALM, which encodes a new member of the AP-3 clathrin assembly protein family. 15 Further investigation of these events will help to establish the roles of these genes in the leukemogenic process.
